Anocca submits application to EMA for pancreatic cancer trial

FDA Grants Orphan Drug Designation to Elicera Therapeutics' ELC-100 for Pancreatic Neuroendocrine Tumors

Elicera Therapeutics' drug candidate ELC-100, an oncolytic virus, has received Orphan Drug Designation (ODD) from the FDA for pancreatic neuroendocrine tumor (NET) treatment.
The ODD provides Elicera with benefits such as tax credits for clinical trials and potential market exclusivity for seven years post-approval.

Regeneron advances anticoagulant antibody pair to late-stage testing - FirstWord Pharma

AnaptysBio pulls out of eczema drug race after Phase II flop - FirstWord Pharma

Anocca Submits Clinical Trial Application to EMA for ANOC-001 in Advanced Pancreatic Cancer

Anocca has submitted a Clinical Trial Application (CTA) to the EMA for its VIDAR-1 Phase I/II trial.
The VIDAR-1 trial will evaluate ANOC-001, a TCR-T cell therapy, in patients with advanced pancreatic cancer.

Can-Fite Doses First Patient in Phase IIa Pancreatic Cancer Trial with Namodenoson

Can-Fite BioPharma has dosed the first patient in its Phase IIa clinical trial evaluating Namodenoson for advanced pancreatic adenocarcinoma.
The open-label, multicenter trial will assess the safety, clinical activity, and pharmacokinetics of oral Namodenoson (25 mg twice daily) in patients who have progressed on first-line therapy.

Can-Fite BioPharma Doses First Patient in Phase IIa Pancreatic Cancer Trial with Namodenoson

Can-Fite BioPharma has dosed the first patient in its Phase IIa clinical trial (NCT06387342) evaluating Namodenoson for advanced pancreatic adenocarcinoma.
The open-label, multicenter trial will assess the safety, clinical activity, and pharmacokinetics of oral Namodenoson (25 mg twice daily) in patients who have progressed on first-line therapy.

Abivax enrols first participant in Phase IIb Crohn's disease drug trial - MSN

Otsuka reports data from Phase III Alzheimer's agitation trial - MSN

EC approves Daiichi Sankyo's Vanflyta for acute myeloid leukaemia - MSN

Anixa Biosciences Plans Phase II Trial for Breast Cancer Vaccine

Anixa Biosciences is set to launch a Phase II clinical trial for its breast cancer vaccine, administered before surgery.
The trial will evaluate the vaccine's efficacy alongside chemotherapy and pembrolizumab, aiming to reduce tumor burden and recurrence.